+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID05112601

Randomized Trial Comparing Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Recurrent Endometrial Cancer with Deficient Mismatch Repair

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

81

Participants Needed

138

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether combining nivolumab with ipilimumab is more effective than using nivolumab alone to shrink tumors in patients with recurrent endometrial carcinoma that has a deficient mismatch repair system dMMR. This phase II trial focuses on patients whose cancer has returned after a period with no detectable disease. The trial investigates how these immunotherapies impact tumor growth by helping the immune system attack cancer cells, addressing an important question for patients with this specific cancer type and genetic profile. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously every three weeks combined with ipilimumab every six weeks for up to eight cycles, followed by nivolumab alone every four weeks. The other group receives nivolumab alone every three weeks for up to eight cycles, then every four weeks thereafter. Patients who achieve a complete response continue nivolumab for an additional 12 months as maintenance therapy. Optional tissue and blood samples are collected, and imaging scans such as CT or MRI are performed throughout the trial. During the study, participants undergo regular monitoring including imaging scans and laboratory tests. Follow-up visits occur every three months for the first two years and every six months for the following three years. Researchers assess progression-free survival, overall survival, tumor response, and treatment side effects for up to five years after enrollment. This long-term follow-up helps evaluate the effects and safety of the immunotherapy combinations in this patient group.

CONDITIONS

Brief Title

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here